625 related articles for article (PubMed ID: 25256594)
1. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study.
Madsen C; Baandrup L; Dehlendorff C; Kjaer SK
Acta Obstet Gynecol Scand; 2015 Jan; 94(1):86-94. PubMed ID: 25256594
[TBL] [Abstract][Full Text] [Related]
2. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
Baandrup L
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
[TBL] [Abstract][Full Text] [Related]
3. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study.
Rice MS; Murphy MA; Vitonis AF; Cramer DW; Titus LJ; Tworoger SS; Terry KL
Int J Cancer; 2013 Nov; 133(10):2415-21. PubMed ID: 23650079
[TBL] [Abstract][Full Text] [Related]
4. Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation-A nationwide case-control study.
Darelius A; Kristjansdottir B; Dahm-Kähler P; Strandell A
Int J Cancer; 2021 Oct; 149(8):1544-1552. PubMed ID: 34152012
[TBL] [Abstract][Full Text] [Related]
5. Salpingectomy and Ovarian Cancer Prevention.
Harris AL
Nurs Womens Health; 2015 Dec-2016 Jan; 19(6):543-9. PubMed ID: 26682662
[TBL] [Abstract][Full Text] [Related]
6. Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
Duus AH; Zheng G; Baandrup L; Faber MT; Kjær SK
Gynecol Oncol; 2023 Oct; 177():125-131. PubMed ID: 37683548
[TBL] [Abstract][Full Text] [Related]
7. Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States.
Mandelbaum RS; Matsuzaki S; Sangara RN; Klar M; Matsushima K; Roman LD; Paulson RJ; Wright JD; Matsuo K
Am J Obstet Gynecol; 2021 Oct; 225(4):399.e1-399.e32. PubMed ID: 34181896
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of opportunistic salpingectomy vs tubal ligation at the time of cesarean delivery.
Venkatesh KK; Clark LH; Stamilio DM
Am J Obstet Gynecol; 2019 Jan; 220(1):106.e1-106.e10. PubMed ID: 30170036
[TBL] [Abstract][Full Text] [Related]
9. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada.
Hanley GE; Kwon JS; Finlayson SJ; Huntsman DG; Miller D; McAlpine JN
Am J Obstet Gynecol; 2018 Aug; 219(2):172.e1-172.e8. PubMed ID: 29852159
[TBL] [Abstract][Full Text] [Related]
10. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage.
Naumann RW; Hughes BN; Brown J; Drury LK; Herzog TJ
Am J Obstet Gynecol; 2021 Oct; 225(4):397.e1-397.e6. PubMed ID: 33798477
[TBL] [Abstract][Full Text] [Related]
11. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies.
Rice MS; Hankinson SE; Tworoger SS
Fertil Steril; 2014 Jul; 102(1):192-198.e3. PubMed ID: 24825424
[TBL] [Abstract][Full Text] [Related]
12. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma.
Lessard-Anderson CR; Handlogten KS; Molitor RJ; Dowdy SC; Cliby WA; Weaver AL; Sauver JS; Bakkum-Gamez JN
Gynecol Oncol; 2014 Dec; 135(3):423-7. PubMed ID: 25316178
[TBL] [Abstract][Full Text] [Related]
13. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States.
Hanley GE; McAlpine JN; Pearce CL; Miller D
Am J Obstet Gynecol; 2017 Mar; 216(3):270.e1-270.e9. PubMed ID: 27810554
[TBL] [Abstract][Full Text] [Related]
14. Salpingectomy as a means to reduce ovarian cancer risk.
Daly MB; Dresher CW; Yates MS; Jeter JM; Karlan BY; Alberts DS; Lu KH
Cancer Prev Res (Phila); 2015 May; 8(5):342-8. PubMed ID: 25586903
[TBL] [Abstract][Full Text] [Related]
15. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
16. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness.
Modugno F; Ness RB; Wheeler JE
Ann Epidemiol; 2001 Nov; 11(8):568-74. PubMed ID: 11709277
[TBL] [Abstract][Full Text] [Related]
17. Trends in incidence of borderline ovarian tumors in Denmark 1978-2006.
Hannibal CG; Huusom LD; Kjaerbye-Thygesen A; Tabor A; Kjaer SK
Acta Obstet Gynecol Scand; 2011 Apr; 90(4):305-12. PubMed ID: 21306323
[TBL] [Abstract][Full Text] [Related]
18. Prescription use of paracetamol and risk for ovarian cancer in Denmark.
Baandrup L; Friis S; Dehlendorff C; Andersen KK; Olsen JH; Kjaer SK
J Natl Cancer Inst; 2014 Jun; 106(6):dju111. PubMed ID: 24848623
[TBL] [Abstract][Full Text] [Related]
19. The Role of Opportunistic Bilateral Salpingectomy vs Tubal Occlusion or Ligation for Ovarian Cancer Prophylaxis.
Ely LK; Truong M
J Minim Invasive Gynecol; 2017; 24(3):371-378. PubMed ID: 28087480
[TBL] [Abstract][Full Text] [Related]
20. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.
Sieh W; Salvador S; McGuire V; Weber RP; Terry KL; Rossing MA; Risch H; Wu AH; Webb PM; Moysich K; Doherty JA; Felberg A; Miller D; Jordan SJ; ; ; Goodman MT; Lurie G; Chang-Claude J; Rudolph A; Kjær SK; Jensen A; Høgdall E; Bandera EV; Olson SH; King MG; Rodriguez-Rodriguez L; Kiemeney LA; Marees T; Massuger LF; van Altena AM; Ness RB; Cramer DW; Pike MC; Pearce CL; Berchuck A; Schildkraut JM; Whittemore AS;
Int J Epidemiol; 2013 Apr; 42(2):579-89. PubMed ID: 23569193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
